Adverse events of monoclonal antibodies used for cancer therapy
M Guan, YP Zhou, JL Sun… - BioMed research …, 2015 - Wiley Online Library
In 1997, the first monoclonal antibody (MoAb), the chimeric anti‐CD20 molecule rituximab,
was approved by the US Food and Drug administration for use in cancer patients. Since …
was approved by the US Food and Drug administration for use in cancer patients. Since …
[HTML][HTML] Combined therapy with thrombospondin-1 type I repeats (3TSR) and chemotherapy induces regression and significantly improves survival in a preclinical …
S Russell, M Duquette, J Liu, R Drapkin… - The FASEB …, 2014 - pmc.ncbi.nlm.nih.gov
Most women are diagnosed with epithelial ovarian cancer (EOC) at advanced stage, where
therapies have limited effectiveness and the long-term survival rate is low. We evaluated the …
therapies have limited effectiveness and the long-term survival rate is low. We evaluated the …
Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer
Objective Adding bevacizumab to cisplatin–paclitaxel for advanced cervical cancer
significantly improves overall and progression-free survival. We evaluated bevacizumab …
significantly improves overall and progression-free survival. We evaluated bevacizumab …
[HTML][HTML] Extreme complications related to bevacizumab use in the treatment of ovarian cancer: a case series from a III level referral centre and review of the literature
LC Turco, G Ferrandina, V Vargiu… - Annals of …, 2020 - ncbi.nlm.nih.gov
In patients undergoing debulking surgery for ovarian cancer (OC), bevacizumab-combined
chemotherapy has been reported to be associated with an increased incidence of adverse …
chemotherapy has been reported to be associated with an increased incidence of adverse …
[HTML][HTML] Anti-VEGF therapy reduces intestinal inflammation in Endoglin heterozygous mice subjected to experimental colitis
DS Ardelean, M Yin, M Jerkic, M Peter, B Ngan… - Angiogenesis, 2014 - Springer
Chronic intestinal inflammation is associated with pathological angiogenesis that further
amplifies the inflammatory response. Vascular endothelial growth factor (VEGF), is a major …
amplifies the inflammatory response. Vascular endothelial growth factor (VEGF), is a major …
A phase II trial of two durations of Bevacizumab added to neoadjuvant gemcitabine for borderline and locally advanced pancreatic cancer
K Sahora, M Schindl, I Kuehrer, A Eisenhut… - Anticancer …, 2014 - ar.iiarjournals.org
Background: We report the results of a phase II trial of adding the anti-ascular endothelial
growth factor (VEGF) bevacizumab to gemcitabine neoadjuvant chemotherapy for patients …
growth factor (VEGF) bevacizumab to gemcitabine neoadjuvant chemotherapy for patients …
[HTML][HTML] Cancer therapy-related complications in the bowel and mesentery: an imaging perspective
EJ Gray, A Darvishzadeh, A Sharma, D Ganeshan… - Abdominal …, 2016 - Springer
Cancer therapy-induced complications in the bowel and mesentery are fairly common. It is
important for clinicians to be aware of these complications and the agents most frequently …
important for clinicians to be aware of these complications and the agents most frequently …
Tumor-Bowel Fistula as a Rare Form of Recurrent Ovarian Cancer—Imaging and Treatment: Preliminary Report
M Jankowska-Lombarska, L Grabowska-Derlatka… - Current …, 2022 - mdpi.com
Background. The aim of this pilot study was to evaluate the value of imaging techniques,
including computed tomography (CT) and magnetic resonance imaging (MRI), in the …
including computed tomography (CT) and magnetic resonance imaging (MRI), in the …
Unintended consequences of systemic and ablative oncologic therapy in the abdomen and pelvis
JC Birch, G Khatri, LM Watumull, YE Arriaga… - Radiographics, 2018 - pubs.rsna.org
Human cancers are genetically complex and diverse. Although advances in oncologic
therapy aim to define and target unique steps in carcinogenesis, oncologists often rely on …
therapy aim to define and target unique steps in carcinogenesis, oncologists often rely on …
[HTML][HTML] Fatal rectovaginal fistula in post-radiotherapy locally advanced cervical cancer patients
CY Wu, LM Tseng, HH Chen, CH Hsieh… - Taiwanese Journal of …, 2022 - Elsevier
Objective To present the detailed history of three cervical cancer patients with rectovaginal
fistula, who had undergone radiotherapy. Cases report A 74-year-old patient with end-stage …
fistula, who had undergone radiotherapy. Cases report A 74-year-old patient with end-stage …